LLY

1,048.36

+1.39%↑

JNJ

244.28

+0.03%↑

ABBV

234.47

+4.3%↑

NVS

163.08

+1.41%↑

MRK

122.45

+0.88%↑

LLY

1,048.36

+1.39%↑

JNJ

244.28

+0.03%↑

ABBV

234.47

+4.3%↑

NVS

163.08

+1.41%↑

MRK

122.45

+0.88%↑

LLY

1,048.36

+1.39%↑

JNJ

244.28

+0.03%↑

ABBV

234.47

+4.3%↑

NVS

163.08

+1.41%↑

MRK

122.45

+0.88%↑

LLY

1,048.36

+1.39%↑

JNJ

244.28

+0.03%↑

ABBV

234.47

+4.3%↑

NVS

163.08

+1.41%↑

MRK

122.45

+0.88%↑

LLY

1,048.36

+1.39%↑

JNJ

244.28

+0.03%↑

ABBV

234.47

+4.3%↑

NVS

163.08

+1.41%↑

MRK

122.45

+0.88%↑

Search

Smith & Nephew PLC ADR

Atidarymo kaina

36.09 1.15

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

35.41

Max

36.21

Pagrindiniai rodikliai

By Trading Economics

Pajamos

296M

Pardavimai

3B

P/E

Sektoriaus vid.

31.586

121.746

Dividendų pajamingumas

2.17

Pelno marža

9.895

Darbuotojai

17,000

EBITDA

723M

Rekomendacijos

By TipRanks

Rekomendacijos

Neutralu

12 mėnesių prognozė

-1.71% downside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

2.17%

2.26%

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

15B

Ankstesnė atidarymo kaina

34.94

Ankstesnė uždarymo kaina

36.09

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bullish Evidence

Smith & Nephew PLC ADR Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-02-12 23:57; UTC

Karštos akcijos

Stocks to Watch: Applied Materials, Arista, DraftKings, Pinterest

2026-02-12 23:35; UTC

Uždarbis
Pagrindinės rinkos jėgos

Arista Networks Surges on AI Networking Demand, Despite Rising Costs

2026-02-12 23:28; UTC

Uždarbis

Applied Materials Profit Rises on Soaring AI Demand -- Update

2026-02-12 21:47; UTC

Uždarbis

Vertex Pharmaceuticals Revenue Climbs on Continued Cystic Fibrosis Demand

2026-02-13 00:00; UTC

Rinkos pokalbiai

ANZ Gets a New Bull as Productivity Prospects Improve -- Market Talk

2026-02-12 23:47; UTC

Rinkos pokalbiai

Nikkei May Fall After AI Concerns Drag Stocks on Wall Street -- Market Talk

2026-02-12 23:38; UTC

Rinkos pokalbiai

Gold Steady; Could Undergo Technical Recovery -- Market Talk

2026-02-12 23:33; UTC

Uždarbis

Coinbase Swings to a Fourth-Quarter Loss Amid Crypto Meltdown -- 2nd Update

2026-02-12 23:09; UTC

Rinkos pokalbiai

South32's Hermosa Review Stokes Spending Fears -- Market Talk

2026-02-12 22:55; UTC

Uždarbis
Karštos akcijos

Applied Materials, DraftKings, Airbnb: Earnings in Focus -- WSJ

2026-02-12 22:46; UTC

Rinkos pokalbiai

Northern Star Outlook Needs Project Done On Time, In Budget -- Market Talk

2026-02-12 22:23; UTC

Uždarbis

Coinbase Swings to a Fourth-Quarter Loss Amid Crypto Meltdown -- Update

2026-02-12 22:15; UTC

Uždarbis

Agnico-Eagle Mines: Gold Production for 2026 and 2027, Expected at 3.3M to 3.5M Ounces Annually, Is Consistent With Previous Guidance, With Offsetting Adjustments Between Mine Sites >AEM.T

2026-02-12 22:15; UTC

Uždarbis

Agnico-Eagle Mines Raises Dividend to 45c >AEM.T

2026-02-12 22:15; UTC

Uždarbis

Agnico-Eagle Mines 4Q Rev $3.56B >AEM.T

2026-02-12 22:15; UTC

Uždarbis

Agnico-Eagle Mines 4Q EPS $3.04 >AEM.T

2026-02-12 22:00; UTC

Uždarbis

AGNICO EAGLE REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS - RECORD QUARTERLY AND ANNUAL FREE CASH FLOW; 2025 PRODUCTION GUIDANCE ACHIEVED; TOTAL 2025 SHAREHOLDER RETURNS OF $1.4 BILLION; DIVIDEND INCREASED BY 12.5%; UPDATED THREE-YEAR GUIDANCE >AEM.T

2026-02-12 22:00; UTC

Uždarbis

Agnico-Eagle Mines 4Q Rev $3.56B >AEM

2026-02-12 22:00; UTC

Uždarbis

Agnico-Eagle Mines 4Q Net $1.52B >AEM

2026-02-12 22:00; UTC

Uždarbis

Agnico-Eagle Mines 4Q Adj EPS $2.70 >AEM

2026-02-12 22:00; UTC

Uždarbis

AGNICO EAGLE REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS - RECORD QUARTERLY AND ANNUAL FREE CASH FLOW; 2025 PRODUCTION GUIDANCE ACHIEVED; TOTAL 2025 SHAREHOLDER RETURNS OF $1.4 BILLION; DIVIDEND INCREASED BY 12.5%; UPDATED THREE-YEAR GUIDANCE >AEM.T

2026-02-12 22:00; UTC

Uždarbis

Agnico-Eagle Mines 4Q EPS $3.04 >AEM

2026-02-12 21:57; UTC

Uždarbis

XP 4Q Rev BRL4.95B >XP

2026-02-12 21:52; UTC

Uždarbis

Coinbase Revenue Falls Short as Crypto Market Sags -- Barrons.com

2026-02-12 21:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2026-02-12 21:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-02-12 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-02-12 21:47; UTC

Uždarbis

Morningstar 4Q Rev $641M >MORN

2026-02-12 21:39; UTC

Uždarbis

Coinbase Revenue Falls Short as Crypto Market Sags -- Barrons.com

2026-02-12 21:38; UTC

Uždarbis

Howmet Stock Jumps. Earnings Show Strength For This Sector. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Smith & Nephew PLC ADR Prognozė

Kainos tikslas

By TipRanks

-1.71% į apačią

12 mėnesių prognozė

Vidutinis 34.46 USD  -1.71%

Aukščiausias 34.91 USD

Žemiausias 34 USD

Remiantis 2 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Smith & Nephew PLC ADR kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

2 ratings

0

Pirkti

2

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

26.64 / 28.37Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Bullish Evidence

Vidutinės trukmės periodas

Bullish Evidence

Ilgalaikis periodas

Bullish Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Smith & Nephew PLC ADR

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
help-icon Live chat